Výsledky vyhledávání - "Lianmeng Kou"

Akademický článek

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation

Autor: Biruk Sintayehu Fanta, Jimma Lenjisa, Theodosia Teo, Lianmeng Kou, Laychiluh Mekonnen, Yuchao Yang, Sunita K. C. Basnet, Ramin Hassankhani, Matthew J. Sykes, Mingfeng Yu, Shudong Wang

Publikováno v: Molecules, Vol 28, Iss 7, p 2951 (2023)

Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the

Externí odkaz: https://doaj.org/article/e7f7255ec5e440348ed681432266d49d

Zobrazit plný text záznamu

Plný text ve formátu HTML

2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation

Autor: Biruk Sintayehu Fanta, Laychiluh Mekonnen, Sunita K.C. Basnet, Theodosia Teo, Jimma Lenjisa, Nishat Z. Khair, Lianmeng Kou, Solomon Tadesse, Matthew J. Sykes, Mingfeng Yu, Shudong Wang

Publikováno v: Bioorganic & Medicinal Chemistry. 80:117158

Refereed/Peer-reviewed Deregulation of cyclin-dependent kinase 2 (CDK2) and its activating partners, cyclins A and E, is associated with the pathogenesis of a myriad of human cancers and with resistance to anticancer drugs including CDK4/6 inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8f63a551dceced78f485f06da01662
https://doi.org/10.1016/j.bmc.2023.117158

Zobrazit plný text záznamu

Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations

Autor: Jasmine D. Karanjia, Lianmeng Kou, Alemwork A. Kebede, Yi Long, Sunita K.C. Basnet, Aleksandra M. Ochnik, Mingfeng Yu, Shudong Wang

Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) is one of the most pursued targets in the treatment of acute myeloid leukaemia (AML) as its gene amplification and mutations, particularly internal tandem duplication (ITD), contribute to t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4d5f6657f1b038a6811349efb468e8
https://hdl.handle.net/11541.2/147361

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání